Inflammatory cytokines at admissionIndependent prognostic markers in patients with acute coronary syndrome and hyperglycaemia

Acute Cardiac Care

Volumn 14, Issue 1, 2012, Pages 13-19

  Cherneva, Zheyna Vlaeva ^a   Denchev, Stefan Veselinov ^a   Gospodinova, Mariana Vasileva ^a   Cakova, Adelina ^a   Cherneva, Radostina Vlaeva ^a  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Hyperglycaemia; Inflammatory cytokines; Prognosis; Surrogate marker

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; CREATINE KINASE MB; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART MUSCLE NECROSIS; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; BLOOD; BULGARIA; CHEMISTRY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BULGARIA; C-REACTIVE PROTEIN; CREATINE KINASE, MB FORM; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PROGNOSIS; TROPONIN T; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857826185     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.3109/17482941.2011.655292     Document Type: Article

References (13)

1. Goldberg P, Bozzo J, Thomas P, A. et al. ' Glucometrics' : Assessing the quality of inpatient glucose management. Diabetes Technol Ther. 2006;8:560-9. (Pubitemid 44946880)
2. Badawi O, Yeung S, Rosenfeld B. Evaluation of glycemic control metrics for intensive care unit populations. Am J Med Qual. 2009;XX:1-10.
3. Vogelzang M, van der Horst I, Nijsten M. Hyperglycaemic index as a tool to assess glucose control: A retrospective study. Crit Care 2004;8:122-7.
4. Hayden M, Tyagi S. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003;2:2.
5. Ancey C, Corbi P, Froger J, Delwail A, Wijdenes J, Gascan H, et al. Secretion ofIL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine 2002;18:199-205. (Pubitemid 34775428)
6. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002;8: RA5-RA12. (Pubitemid 34136335)
7. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010;31:777-783.
8. Bassuk Sh, Rifai N, Ridker P. High sensitive C-reactive protein: Clinical importance Curr Probl Cardiol. 2004;29:439-93. (Pubitemid 39055635)
9. Dungan KM, Braithwaite SS, Preiser J-C. Stress hyperglycaemia. Lancet 2009;373:1798-807.
10. Zacho J, Hansen A, Nordestgaard B. C-reactive protein and allcause mortality-the Copenhagen city heart study. Eur Heart J. 2010;31:1624-32.
11. C hazova T, Masenko V, Zykov K, Golitsyna TIu. The role of inflammation factors in development of ACS in patients with type 2 diabetes mellitus and impaired glucose tolerance. 2007;6:60-4.
12. D uarte EL, Pellanda, V. Portal. Inflammatory, lipid, and metabolic profie in acute ischemic syndrome. Correlation with hospital and posthospital events. Arq Bras Cardiol. 2005;84:122-9.
13. Roubille F, Samri A, Cornillet L, Sportouch-Dukhan C, Davy JM, Raczka F, et al. Routinely-feasible multiple biomarkers score to predict prognosis aft er revascularized STEMI. Eur J Int Med. 2010;21:131-6.